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Among retinoic acid receptors (RARs) 0'. /3. and y. 
the messenger RNA level of RAR-y is the most 
readily detectable by Northern blotting in human and 
mouse skin. This observation suggests that RAR-y 
may play a critical role in the modulation of the 
therapeutic benefits and side effects of retinoids in 
skin. To test this hypothesis. 11 RAR-y selective 
retinoids were synthesized based on three related 
structures. Each compound was found to prefer 
RAR-y when assessed by retinoid-induced transcrip-
tional activity (RAR-y > RAR-/3 > RAR-O'). The 
apparent Kd for binding to reconlbinant receptor 
protein was found to follow a sintilar trend. To 
correlate this receptor selectivity with in vivo activity. 
T he recent discovery of three different retinoic acid receptors (RAR-a, -(3, and -')I) [1-5] raises the questions of whether each receptor plays a distinct biologic role and, if so, whether the retinoid efficacy [6-10] and side effects [11 ,12] can be separated. To 
address these questions, receptor-selective or specific retinoids are 
needed. Despite the high level of h omology among the three RAIl... 
receptors, RAR-y--selective retinoids have been reported [13,14]. 
One of the most commonly used animal models for evaluation of 
the in vivo efficacy of retinoids is the Rhino mouse utriculi reduction 
assay. The Rhino mouse is a strain of the hairless mouse that 
possesses large comedones resembling those seen in acne in humans 
[15,1 6]. The comedones decrease ill size in a dose-dependent 
manner with the addition of retinoic acid, and this decrease is taken 
as predictive of retinoid efficacy in acne . Yet the mechanism by 
which retinoic acid mediates tills response is unknown . 
Another commonly used ill IJivo system for evaluation of retinoid 
activity is the rabbit irritation model [17]. Th.is model monitors side 
effects such as erythema, edema, and scaling, commonly associated 
with retinoid treatment [11,12]. T h e molecular basis of retinoid-
Manuscript received October 12, 1994; final revision received December 
19, 1994; accepted for publication January 10, 1995. 
This work was presented in part at the 55th Annual Meeting of the 
Society for Investigative Dermatology, Baltimore, MD. 
Reprint requests to: Dr. Simon Chen, Bristol Myers Squibb Pharmaceu-
tical Research Institute, 100 Forest Avenue, Buff.l l0, NY 14213. 
Abbreviation: t-RA, aU-trans retinoic acid . 
"\" Simon Chen and Jacek Ostrowski contributed equally to this work. 
the compounds were tested topically in the Rhino 
mouse utriculi reduction and rabbit irritation mod-
els. two assays widely used to screen retinoids for 
efficacy and side effects. respectively. The results 
indicated that for these compounds. both efficacy in 
the utriculi reduction assay and irritation potential in 
rabbits correlated positively with the RAR-y transac-
tivation activity, with r2 of 0.9 and 0.8, respectively. 
These data suggest that RAR-y is an important reg-
ulator of retinoic acid efficacy in skin and further, 
that the irritation associated with the use of retinoids 
is most likely a receptor-mediated process. Key lVord: 
Rhino tnOllse. ] Itwest DeYnlatol 104:779-783, 1995 
induced irritation has long been a matter of speculation because no 
sin gle biochemical marker defines tills process. 
The efficacy and side effects found in the c1llllcal use of retinoids 
and assessed using these animal models may be mediated through 
different receptors. Synthetic retinoids with preferential affinity for 
a given receptor would be useful for defining the roles of each 
receptor in these animal models. In addition, it may be possible to 
optimize efficacy while reducing unwanted side effects in the design 
of future retinoid analogs. To test tills hypothesis, we synthesized 
and characterized 11 retinoids derive d from three known chemo-
types [13 ,14,18] as RAR-')I selective. A close correlation was fowld 
between RAR-y--mediatcd transcriptional activity, receptor bind-
ing, and efficacy in both the Rhino model and the rabbit irritation 
model. These results suggest th.at RAR-')I mediates inlportant 
retinoid-induced effects in the skin, as might b e predicted by the 
tissue distribution of this receptor [19], and that retinoid-induced 
skin irritation is most likely a receptor-mediated event. 
MATERIALS AND METHODS 
Animals Male New Zealand White rabbits, 10-12 weeks old, were 
purchased from the MVR f.~nn (Loudonville, OH). Pathogen-free 9-12-
week-old female hairless Rhino mice (hr'h/hr'h) were bred by Taconic 
Laboratories (Germantown, NY). Animals were kept on a 12-hour light/ 
dark cycle. The animal rooms were suppLied with yeUow lights to avoid 
retinoid photoisomel;zation. All experiments were perfol111ed in accordance 
with National Institutes of Health guidelines for animal handling. 
Chemicals AU chemicals nsed were of reagent grade and obtained from 
Sigma Chemical Co . (St. Louis, MO). All-trans retinoic acid (t-RA) was 
purchased from BASF (Wyandotte. MI). Compounds 1, 7, and 11 were 
prepared as reported previously [13 , 14,18] . All other synthetic retinoids 
were synthesized at BMS Central Chemistry (Wallingford. CT). 
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Transactivation Direct Binding Rhino Rabbit 
# Structure EC50(nM) Apparent Kd (nM) E030 IS3 
a y a p y (mM) (mM) 
IRA 
~~' 
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II 
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II 
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w~ 
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" ~~' 
7 NA 575 163 NA 654 87 0.22 0.98 
II 
~LWII 
8 I I NA 363 58 NA 491 97 0.14 0.98 
! 
0 11 
HcnanLiomcr 
~' 9 I I NA NA 450 NA 4065 1122 0.75 74 
" 
(+)cnardomcl 
~~' 10 r I NA NA 300 NA 1350 400 0.58 29 I 
II 
.0" 
11 ~~, NA 450 30 900 50 5 0.072 0.037 
-NA _ not acti ve -NO not detennmed 
Figure 1. III vitro and ill IIivo activity ofRAR-y-sclective retinoids. 
T he 1"lAR.-y selectivity of the 11 retino ids was demonstrated in a transien t 
transacti va tion chloramphen icol ace tyl transferase assay in HeLa ce ll s and by 
binding to recombinant receptor protein . /11 I/il/o e ffi c;,cy and irri tation were 
tested in the R.hino mouse utri cul i reduction (n = 5) and the rabbit repeat 
irri tation (n = 6) experiments, respectively. 
III Vitro Assays R.etinoid se lectivity was assessed using a transactivation 
assay and a direct binding assay . In the transactivation assay, Hc La cell s were 
transfected with a GaI4-R.AR (DEF) a, {3, or y chimeric receptor, alo ng 
with a reporter plasmid contain ing thc Ga l4 responsc clement and a 
chlor;omphenicol acetyl transferase reporter gene. {3-galactosidase was in-
cluded as a contro l for transfection efficiency. Transfected ce ll s were grown 
in the presence of the test retinoid for 24 h, then harvested and assayed for 
chloramphenicol acetyltransferase concentration using an enzyme-linked 
immunosorben t assay (5' to 3', Inc. , Philadelphia , PAl . In each experiment, 
a t-RA dose-response was included as the positive control. T he ECS() listed 
in Fig 1 is the concentration of the test material reaching 50'l{, of t- l'l...A 
maximum stimulation at 10- 6 M . In the case ofRAR-a of compound 2, the 
transactivation activ ity at 10- 6 M was 45°AI oft-RA maximum , and the daw 
were extrapo lated slightl y above 10 - (' M to give the esti mated K" of 2.2 
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J-LM . Compounds with a transactivation activity well below 50'XI of t- l"lA 
activity at 10- 6 M are listed as "not active" in Fig 1. 
For the binding assay, recombinant I"lAR protein was expressed in 
Escherichin coli, and the apparent dis sociation constant was determined by the 
charcoal absorption method [20]. BrieRy, serial di lutions of the test retinoids 
(10 - 1 I to 10- s M) were made in dimetll ylsulfoxide in a volume of 1 00 pL. 
T welve micrograms of crude cytosolic extract prepared from pET15b/ 
hRAR.-a, -{3, or -y prepared protein was used for each data point. All 
reactions were carried o ut in binding buffer (60 mM Na lmidazole, 500 mM 
NaCI, 20 mM Tris, pH 7.9) for 14-16 h at 4°C in a final volume ofl mL. 
Unbound r l-l]- J"lA was removed by add ition of 0.5 mL of equivalent-s ized 
d ex tran-treated charcoal (fina l concentration 3% [wt/volD for 15 min at 
4°C [21]. One half milliliter of the supernatant was removed , added to 12 
nnL of ReadySafeTM scintillation cocktail (Beckman), and counted in an 
LS6500 scinti llation counter (Beckman) . 
III Villa Assays Retinoids in 50 ,...1 ethanol were applied topically to the 
central do rsum of R.hino mice [16J once daily for 5 d. Seventy- two hours 
a.fter the last treatment, the animals were sacrifi ced by CO2 inha lation. A 
full-thickness skin biopsy specimen (7 /8 in.) was removed from the 
treatment site. T he ep iderm is was separated from the dermis by overnight 
incubation in 0.5% acetic acid at 4°C. Epidermal sheets were fixed in 10'Yu 
formalin, dehydrated with ethano l, and cleared in xylene. The d iameter of 
40 utricuti was measured for each sample of processed epidermis with an 
iJ11age analyzer (Image Measure; Microscience, Federa l Way, WA). For 
each retinoid , a dose ranging from 3.3 ,...M to 3 .3 mM was tested. T he 
p ercent utri culi reduction was defined as the percent decrease of utriculi 
diamete r compared with that of the ethano l control. T he ED " I va luc (dose 
rendering 30% reduction of u triculi diamete r, i.e., half-maxima l biologic 
response) was calcu lated by interpolation of the dose- response curve us ing 
li near regression analysis. Five animals were used in each group. 
The irritation potentia l for each of the test compounds was assessed using 
the 14-day repea t rabbit irritation assay [17]. Each rabbit was clipped at four 
dorsal sites (16 cm2 for each site). Each site was randomized for treatment 
with a retinoid at three concentrations, and t- l"lA at 0. ;l3 mM was used as 
a. positive control. Each retinoid was app lied topica ll y in ethanol (200 ,...L) 
o nce daily for 14 consecutive days. Each day before administering the 
compound , the degree of erythema, edema, and sca ling was assessed 
visuall y using the Draize 0-4 grading sca le [1 7). T he global score for each 
treatment was defined as the mean dai ly sum of the erythema, edema, and 
scalin g scores. T he IS3 value (the concentration producing a global score o f 
3) was calculated from the dose-response curve using linear regress ion 
a na lysis. Si.." anima ls were used in each treatment group. 
R E SULTS 
RAR-,), Selectivity E leven retinoids in thrce structura l ch emo-
types were synthes ized and e valuated for RAR selectivity (Fig 1). 
'Th e structural ch emotypes included a llylic alcohol' (compounds 
1-6), h ydroxymethyl naphthoate (compoun ds 7-10), an d oxime 
t1aphthoatc (compound 11) [13 ,14,18]. Because of the spatial 
orientation of the hydroxyl group, a ll threc c hcmotypes can e xjst in 
t wO isomeric fo rms. Compou nds 1-7 and 10 w e re evalu ated to be 
racemic mixtures. Compound 7 was further resolved to e ithe r the 
S( - ) e nantiomer (compound 8) or the R( + ) e n antiomer (com-
pound 9). The oxime compound 11 was tested as a 1:1 mixturc of 
the E and Z isomers. 
R e tinoid se lectiv ity for th e three RARs was first determined by 
a transicnt transactivation assay in HeLa cells. All 11 retinoids were 
c hara c terized to be RAR-')' se lective in thi s assay, with RAR-')' 
transactivation ac tivity g reater than that of RAR-a and RAR-f3 
(Fig 1) . Thjs selec tivity was examin ed further in a d irect b inding 
assay in whic h th e receptor afriruty was measured by binding to the 
J'ecombinant receptor proteins . In general, the RAR-')' se lectiv ity of 
these 11 compounds was re flected in both assays, w ith a minor 
discrepancy in compound 4. In the direct binding assay, thjs 
compound showe d simil ar affi ni ty for RAR-f3 and RAR-')' instead 
of a preferen ce for RAR-')'. It should b e pointed out, h owever, that 
c ompound 4 exhibited the lowest separatio n betwee n RAR-f3 and 
RAR-')' in the transac tivation assay. T his compound therefore was 
t h e least se lcctive among the 11 test retinoids . 
To illu strate the receptor se lec tivity of thc tes t compounds, 
transactivation of a representativc compound (oxime compound 
11) is shown in Fig 2. Compound 11 c1carly d emonstrated a 
preference for RAR-')'. Tra n sactivation mcdiated th rough RAR-f3 
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Figure 2_ Dlustration of RAR-l' selectivity of a representative 
retinoid (oxinte compound 11) in the transient transactivation 
assay_ Data represent m ean ± SD from three separate experiments. 
by this retinoid was considerably lower than for RAR-y, and none 
was detected in RAR-a . The RAR-y selectivity of tlus compound 
is also seen in its affinity . T he apparent KdS of compound 11 for 
RAR-a, -{3, and -y were 900, 50, and 5 nM, respectively (Fig 1)_ 
Overall , eight of the 11 compounds exlubi ted minimal RAlt-Q' 
transactivation activity up to 10 - 6 M, and three compounds 
(compounds 5, 9, and 10) also showed no RAR-,B-mediated 
activity. All of the 11 rerinoids had transactivation activities in the 
order of l~-y > 1~-{3 > RAR-a . In contrast, the natural 
ligand t-RA showed similar preference for bind.ing to the three 
receptors, with RAR-a transactivation activity only slightly lower 
tllan those of RAR-{3 and -y (Fig 1). 
III Vitro and III Vivo Correlation Each of the 11 RAR-y-
selective retinoids was tested in the RlUno mouse utriculi reduction 
assay and in the rabbit irritation model (Fig 1). Typical dose 
responses in these assays are illustra ted in Fig 3, using the oxime 
compound 11 as an example. At 3.3 mM, the maximum effects of 
potent retinoids such as t-RA and the oxime compound 11 were 
approximately 60% in the Rluno utriculi reduction assay, with a 
corresponding global irritation score of 6-7 in the rabbit . T he 
half-maximum concentrations of these ass,lys are therefore reported 
as ED30 and IS3 , the concentration of the test retinoids effecting a 
30% utriculi reduction effect or an irritation score of3, respectively_ 
The compounds chosen for study demonstrated a wide range of 
potencies in transactivation for RAR-y and in the ;11 11 ; 110 animal 
models. To draw correlations, we compared the ;'1 11;110 potencies 
for both utriculi reduction and skin irritation with the ECso values 
determined in the transient transactivation assay. As seen in Figs 4 
and 5, both ;11 11; 110 assays correlated positively with RAR-y 
transactivation activity. The correlation coefi:icient r was 0 .94 fot 
utriculi reduction and 0.87 for rabbit irritation (r2, the coefficient of 
determination, was 0 .9 and 0.8, respectively). Similar correlations 
also existed between apparent Kd and the ;11 IIhlo end points, with r~ 
equal to 0.7 for utriculi reduction and 0.9 for rabbit irritation 
(graphs not shown). 
In addition to the high r2 value, the ;IL 11 ;110/;11 II ; tro corre lation is 
reflected in some structure-activ ity relations, in which a subtle 
change in the retinoid structure affects transactivation activity, 
binding affuuty, and ;11 V;II0 potency in a similar marll1er. The first 
example is the enantiomer pair compounds 8 and 9. The S( - ) 
enantiomer compound 8 was considerably more active than the 
R( +) compound 9. The second example is the case of fluorination. 
When compounds 1 and 7 were fluorinated to compounds 2 and 
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J'igure 3. Demonstration of ill l,ivlI activity of a representative 
"etittoid (oxime compound 11). a) Dose-response curve in the Rhino 
mouse utriculi reduction assay (n = 5) . b) Dose-response evaluation of 
rabbit global irritation score after repeat doses (11 = 6) . C losed squares, 
c ompound 11 ; opell squares, t-RA; " l'Or bars. SOs. 
10, respectively, both ill "jllo and ;11 ,,;tro activity was markedly 
reduced (Fig 1). 
It is clear from Fig 1 tllat although all 11 rerinoids showed 
preference for RAR-y in the transactivation assay, most of these 
compounds also have RAR-{3 activity and. i.n some cases, RAR-a 
~ctivity as well . The data in Fig I , however, argue that tile ;11 IJi,IO 
~ctivity of these retinoids CaJU10t be explained by their RAR-a or 
RAR-{3 activi ty. First of all, the eight rerinoids witll little or no 
RAR-a transactivation activity exhibi ted various levels of utriculi 
reduction or irritation activity. A notable example is tlle oxime 
compound 11, which is very potent ;11 11;'10 but has no RAR-a 
:lctivity. Furthermore, correlation plots for RAR-a and RAR-{3 
c:ransactivation and binding activity with the two ;11 ,Jivo assays 
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Figure 4. RAR-y transactivation correlates with Rhino mouse 
utriculi reduction activity_ T he ;11 Vitro/;II V;IIO correlations of the t 1 
RAR-y-selective retinoids (closed siJllares) arc made between the transacti-
vation ECso a.nd the Rhino mouse utriculi reduc tion ED)O values. r2 = 0.9. 
The numbers indicate the compound numbers as seen in Fig 1. For 
comparison, t-RA activity is shown (opell siJllare). 
showed no correlation , with r2 values of 0.3 or lower (graphs not 
shown). 
DISCUSSION 
The results of tlus study indicate that retinoid efficacy in the R1uno 
mouse model and irritation in the rabbit correlate with RAR-y-
mediated transcription activation . In addition to the high r2 values, 
the tight regulation ofRAR-y on ill. IIirlO activity is demonstrated in 
the structure-activity relation. In several cases, the structural dif-
feren ces between the test retinoids sensitively modulated both in 
lIitro and ill vhl o RAR-y activity. The most interesting examples are 
the two hydroxymethyl naphthoate enantiomers (compounds 8 and 
9, to be published). The S( - ) enantiomer compound 8 is consid-
erably more active than the R( +) compound 9 ill. vivo and in 
RAR-y activity. Another observation is that fluorination in the 
position ortho to the linker region decreases the efficacy. Tlus was 
seen in the allylic alcohol series (compounds 1 and 2) and in the 
hydrol\.'ym ethyl naphthoate series (compounds 7 and 10) . In both 
pairs, the addition of a fluorine reduced both the ill vitro and ill IIivo 
activity. 
The nature of retinoid-induced irritation is not well understood. 
Because severa l other non-retinoid compounds such as sodium 
dodecylsulfate generate similar irritation in skin [22], presumably 
by a physicochemical mechanism, it is possible that retinoids induce 
irritation in a similar way. Figures 1 and 5 show that the irritation 
potential of test rerinoids correlates well with their in vitro RAR-y 
activity. Because the test rerinoids are structurally related, tlus result 
suggests that re tinoid-induced irritation is a receptor-mediated 
phenomenon and is not related to the physicochemical properties of 
tlus class of compounds. The skin irritation reported with non-
retinoid compounds, such as sodium dodecylsulfate [22], is mO'st 
likely mediated through a different mechanjsm. 
The functional involvement ofRAR-y in skin is consistent with 
its abundant expression in this organ [19]. T he link between ill IIivo 
potency and RAR-y but not RAR-a or RAR-J3 activity, as shown 
in this study, conf1ITl1s that under physiologic conditions, RAR-y is 
the predominant receptor for retinoid-mediated biologic response 
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Figure 5. RAR-y transactivation ECso's correlate with rabbit irri-
tation IS3 values for the RAR-y-selective retil10ids (closed squa,oes). 
r2 = 0.8. The nnmbers indica te the compound numbers as seen in Fig 1. For 
comparison, t-RA activity is shown (opell siJllare). 
in the skin. However, these results still calmot exclude the possi-
bility that RAR-a and RAR-J3 may also be able to ilutiate a 
derl11atoiogic response . The three receptors m ay have overlapping 
functions in the two i/l. 11;110 models monitored. RAR-a and RAR-J3 
specific compounds, with little or no RAR-y activity, are needed to 
address this question. 
Finally, although the data presented here do not demonstrate a 
separation between efficacy and irritation with RAR-y-selective 
retinoids, the question remains whether a RAR-y-selective/spe-
cific compound of a difFerent chel110type may distinguish the 
therapeutic benefits from the side efFects. Alternatively, it may be 
possible to separate these effects using combinations of other 
receptor preferences to design a compound with a better derma to-
logic profile. Compounds with these characteristics are curren tly 
being evaluated . 
W e tlrallk K. Trmllposclr mrd R . BOlllley Jar rel/;e", oj ,Ire ",mll,script alld lrelJijiti 
d;sCIIss;olls;}. Lllpisella, J. Driscoll, alld J. Rholle Jar help ;11 dClle/op"rcllt oj tI,e 
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